

# 葡萄王生技

### **Investor Presentation**

April 2019

confidential

### Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to
  proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective
  investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any
  appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to
  provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or
  omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forwardlooking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forwardlooking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



# "Why Invest in Us?

- We are a leading health food manufacturer in Taiwan with product development strength focusing on probiotics and herbal-based supplements.
- We are one of the few companies in Taiwan that possess the capability to produce our own raw materials, manufacture our product and distribute through our own brands and channels.
- We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both probiotics and mushroom-based supplements.
- We also operate the second largest direct-selling company in Taiwan Pro-Partner – with a 2016 market share of 9.8%.
- We have delivered a solid earnings CAGR of 23% in 2008-2018 averaging a 21% ROE during the same period.
- We are committed to return our earnings back to our shareholders, we have maintained more than 60% dividend payout in the past five years.
- We strive to maintain a double digit growth rate through continuous market share gain by Pro-Partner and growth in our OEM/ODM businesses in China and overseas markets.





### 葡萄王生技

#### **Company Background**

confidential

# **Company Milestones**

葡萄王生技

• 2008 - Pro-Partner's revenue reached NT\$1.6bn, surpassed Grape King for first time and ranked No.8 among Taiwan direct selling companies.	Center Plant 3 was completed. Total fermentation capacity increased to 275 tons.	<b>2013</b> - Pro-Partner reached NT\$5bn sales, +28% YoY, ranked No.3 among direct selling companies in Taiwan and No.66 in global direct selling company ranking.	<ul> <li>2015 - Pro Partner's revenue reached NT\$6.7bn, ranked as No. 2 among direct selling companies in Taiwan.</li> <li>2015 - Grape King is selected as Forbes "Asia's 200 Best Under A Billion" for two consecutive years.</li> </ul>	<ul> <li>international awards from 7 countries.</li> <li>2017 – Grape King's first tourist factory opened in July.</li> </ul>
<ul> <li>1971 - Grape King Co. Ltd. was founded.</li> <li>1982 - Listed on Taiwan Stock Exchange.</li> <li>1991 - Establishment of the Bio Engineering Center</li> </ul>	<ul> <li><b>2011</b> 2012</li> <li><b>2012</b> - Program revenue resched 2.2bn and ed No.6 among t selling banies in an.</li> <li><b>2012</b> - Program revenue rescaled to the selling com the transmission of the selling com the transmission of the selling com the transmission of the selling com the s</li></ul>	<ul> <li>Partner's ached ranked g direct panies in d No.83 on I 100 list.</li> <li>2014 – C succeed become Chairma</li> <li>2014 - P reached no.2 direct in Taiwa formed a Yunnan I (000538 TCM corr develop</li> <li>2014 - G</li> </ul>	<ul> <li>Dr. Andrew Tseng ed his father to the CEO and n of Grape King.</li> <li>CO ro-Partner's revenue NT\$ 5.8bn, ranked ect selling company n. 2014 - Grape King a partnership with Baiyao Group CH), the largest mpany China to co- products.</li> <li>CO rape King is selected is "Asia's 200 Best</li> <li>CO NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co NT as co So So So So So So So So So So So So So</li></ul>	2017 Offe - Pro Partner's revenue reached T\$8.2bn (+22% YoY), and has remained the largest domestic direct selling ompany in Taiwan since 2009. Offe - Grape King's new plant at ngzhen started operation in eptember. Offe - Grape King is the only company in tiwan to be selected as "Asia's Fastest D Bioscience Companies in Asia" by oSpectrum magazine.

健康 Health

# Company Overview

- Our Group is composed of three business units:
  - Grape King Taiwan (retail sales channel, OEM/ODM business)
  - Pro-Partner (direct selling channel)
  - Grape King Shanghai (OEM/ODM business)
- Since 2008, Pro-Partner has experienced an explosive growth thanks to robust member growth and successful product launches.
- However, Grape King is the locus of all key ingredient design, formulation, and production for the whole Group.



#### We have a Complete Product Range





# <sup>44</sup> R&D Backed by Patents and Papers

We have acquired more than **52 patents** and published over **20 research papers** We have also acquired more than 10 TFDA Health Food certifications on our products

Recent Acquired Patent	Country	Number	Approval Date
An Active Substance <b>for Treating Dementia</b> , Its Preparation Method, Pharmaceutical Compound and Preparation Method	R.O.C.	1605819	2017/11/21
The Active Substance of Cicada for Promoting Hepatocyte Proliferation	R.O.C.	1601824	2017/10/11
Particles with Lactobacillus Embedded by Mycelium of Hericium Erinaceus which Can Improve the Nerve Growth- Factor	China	ZL201620459984.4	2017/6/6
The Active Substance of Antrodia Camphorate Mycelium for <b>Protecting Nerve Cells</b> , and Its Pharmaceutical Compounds	R.O.C.	1562782	2016/12/21
An Active Substance of Antrodia Camphorate for <b>Reducing Drug Resistance of Cancer</b> <b>Cells</b> and Its Compounds	R.O.C.	1551291	2016/10/1
Paper	Journal		
<b>Paper</b> Efficacy and safety of oral Antrodia cinnamomea mycelium in mildly hypertensive adults: A randomized controlled pilot clinical study.		al of Integrative Med	icine.2016
Efficacy and safety of oral Antrodia cinnamomea mycelium in mildly hypertensive	European Journ International Jo	al of Integrative Med urnal of Pharmacy ar Sciences.2016. 8(6):	nd
Efficacy and safety of oral Antrodia cinnamomea mycelium in mildly hypertensive adults: A randomized controlled pilot clinical study. A 90-Day subchronic toxicological assessment of deinococcus grandis fermented	European Jourr International Jo Pharmaceutical	ournal of Pharmacy ar Sciences.2016. 8(6): ournal of Medicinal M	ıd 207-215
Efficacy and safety of oral Antrodia cinnamomea mycelium in mildly hypertensive adults: A randomized controlled pilot clinical study. A 90-Day subchronic toxicological assessment of deinococcus grandis fermented soymilk in Sprague-dawley rats. A 90-Day Subchronic Toxicity Study of Submerged Mycelial Culture of Cordyceps	European Journ International Jo Pharmaceutical International Jo 2015. 17(8): 77 International Jo	ournal of Pharmacy ar Sciences.2016. 8(6): ournal of Medicinal M	nd 207-215 ushrooms. nd

Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague–Dawley rats.

Food and Chemical Toxicology. 2014.70:61-67



#### State-of-the-Art Research & Production

#### **Grape King Bio-Tech Research Institute**











**Optical microscope** 

**High Performance Liquid** Chromatography

Centrifuge

**PCR Machine** 

Shaker

#### Grape King Bio-Tech Specialist Fermentation, Cultivation and Manufacturing



**500 Liters Fermentor** 



**50 Tons Fermentor** 



**High Speed Mixer** 



**Centrifugal Separator** 



**Membrane Filtration System** 



**150 Liters Freeze-Dryer** 



#### **Capsule Packaging Line**



**Sachet Packaging Line** 



**Glass Bottle Packaging** 



**PKL Aseptic Packaging Line** 





Line

### **Grape King Brand Sales Channels**


10



### **Grape King Diverse Product Portfolio**



#### Grape King Key Products Sales Breakdown



### Pro-Partner Overview

Largest domestic direct selling company in Taiwan based on revenue

Second largest overall direct selling company (including global companies) in Taiwan





2

No. 56 in the worldwide direct selling company rankings for 2016


210,000

**Currently have over 210,000 members** 



### **Pro-Partner Overview**


- Established in 1993, Pro-Partner was initially 100% owned by Grape King.
- In 1998, a capital injection was completed by the new management team, with the management team now owning 40% of Pro-Partner.
- To date, Pro-Partner remains one of the fastest growing direct selling companies in Taiwan, having delivered a 21% sales CAGR from 2008 to 2017.
- Pro-Partner products are manufactured using more complicated and high-end formulas vs. Grape King brands, hence the products are also more expensive.



#### Pro-Partner Products - More Complex Formulas

Probiotics & Prebiotics	Super 13 Probiotics & Prebiotics	995 Bio-tech Nourishment	Antrodia Bio Aid
Promote healthy digestive system and suppress allergy	Promote healthy digestive system and suppress allergy	Post operative convalescence	Post operative convalescence
Pro-Partner Meal Supplement	Lion's Mane Mushroom Powder	Bai Ke Sz	Wei-Jie
Nutrition supply, restore physical strength	Promote brain health and cognitive function	Promote heathy respiratory system	Promote stomach health
<b>前 葡 萄 王 生 技</b>	Tec	科技 hnology	健康 Health

#### Pro-Partner Key Products Sales Breakdown



#### How is Pro-Partner different from other direct selling companies?



	Traditional Direct Selling Business	Pro-Partner
Products purchase	<ul> <li>x Minimum purchase requirement.</li> <li>x Initial investment could be significant.</li> <li>x Members may need to bear P&amp;L risk.</li> </ul>	<ul> <li>No minimum purchase requirement.</li> <li>Members buy products directly from the company, thus, no inventory pressure.</li> </ul>
Products' uniqueness	<ul> <li>x Low entry barrier for products.</li> <li>x Products lack national certifications.</li> <li>x Production is mostly outsourced.</li> </ul>	<ul> <li>✓ Products are bio-researched and engineered</li> <li>✓ Symbol of National Quality (SNQ) and Taiwar FDA health food certified.</li> <li>✓ Products are mostly manufactured in-house.</li> </ul>
Membership/ Training	<ul> <li>x Members may need to pay training fees.</li> <li>x High drop out rate of members.</li> <li>x Inconsistent training quality.</li> </ul>	<ul> <li>All the trainings and venues are held by the company and free to members.</li> <li>Hight retention rate of members.</li> </ul>
Compensation	<ul> <li>x Opaque compensation structure.</li> <li>x Compensation scores can not be accumulated.</li> <li>x Compensation calculation and eligibility is different among membership status.</li> </ul>	<ul> <li>Transparent compensation structure.</li> <li>All purchases will be recorded as scores for compensation and will not reset to zero.</li> <li>All compensation are paid accordingly to each member's sales contribution to the company.</li> <li>All compensation are paid directly to the members by the company.</li> </ul>
Support	<ul> <li>x Lack of dedicated customer services.</li> <li>x Lack of local office support.</li> <li>x Poor return and refund policies.</li> </ul>	<ul> <li>Pro-Partner is supported and managed by Grape King, a well-respected health food company in Taiwan with 48 years of history.</li> </ul>



"



#### How is Pro-Partner different from other direct selling companies?


- Nearly 78% of Pro-Partner's sales are contributed by old members.
- Our members retention rate in the past three years are more than 75%, which is a remarkedly high number in the direct selling industry.
- The growth rate of our executive distributors are similar to the growth rate of our members in the past five years. This imply that our members are proportionally promoted each year based on their contribution to the group.
- All of these data are proof of that we are a product-driven direct selling company.



# Grape King Shanghai Overview

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- However, a change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- The company has five products of its own brand certified by the China FDA with "Blue Hat" registration, a strict requirement for all health foods and supplement. The company is planning on launching these products to the market.

Grape King Shanghai operating profit (Rmb m)



### Grape King's Competitive Strengths

20






# 葡萄王生技

**Industry Trends** 

confidential

### **Taiwan Health Food Industry**

- Taiwan's heath food industry saw a 7.5% CAGR from 2003-2017.
- The industry will continue to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.
- We have been gaining marketing share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.



Grape King's market share in Taiwan health food industry											
	2013	2014	2015	2016	2017						
Taiwan health food	4.90%	5.19%	5.44%	5.99%	5.78%						
Mushroom	32.06%	31.46%	32.33%	36.61%	38.54%						
Probiotics	13.89%	20.92%	31.54%	35.78%	39.57%						
Energy drink	12.23%	11.70%	13.94%	14.89%	13.71%						


Source: AC Nielsen, Company data



# **Taiwan Direct Selling Industry**

- Taiwan is ranked in the top 15 markets for direct selling globally. The direct selling industry in Taiwan delivered 6% 2010-2016 CAGR, with health food accounting for nearly 60% of the value.
- Direct selling in Taiwan is strictly regulated particularly in 1) product and price (mark-up on pricing); 2) compensation structure (distribution of profit).
- It is illegal in Taiwan to produce earnings by simply introducing new participants instead of engaging in promotion and selling goods or services at reasonable market pricing, and companies in violation of this may be subject to imprisonment and/or fines.

Rank	Country	2015 Retail sales (US\$bn)	3-Year CAGR
1	United States	36.12	4.5%
2	China	35.46	22.0%
3	South Korea	16.89	7.5%
4	Germany	15.19	5.2%
5	Japan	14.66	-0.7%
6	Brazil	9.13	2.1%
7	Mexico	6.93	4.7%
8	France	4.59	2.5%
9	Malaysia	4.44	9.4%
10	United Kingdom	4.04	9.8%
11	Taiwan	3.35	6.6%
12	Italy	2.93	4.7%



Source: World Federation of Direct Selling Association



# **Taiwan Direct Selling Industry**

- While Taiwan's direct selling industry delivered a 6% CAGR during 2010-2016, Pro-Partner delivered a 22% CAGR during the same period.
- Pro-Partner is the only domestic company among the top 10, with the remainder being foreign companies. Top 10 companies accounted for roughly 60% of the industry.
- Pro-Partner currently has more than 210k members as at the end of 2018, while market leader Amway has around 350k members.
- Among the market leaders, Pro-Partner has the highest sales per product.

Taiwan Direct Selling Ranking and Market Share %				e %			Sales		Sales		
	2012	2013	2014	2015	2016	2016 Company		contribution per		contribution per product	
Amway	1 (15.1%)	1 (15.2%)	1 (14.9%)	1 (14.7%)	1 (13.45%)		('000)	member (NT\$)	FIGUUCIS	(NT\$m)	
Pro-Partner	4 (6.4%)	4 (7.6%)	2 (8.2%)	2 (8.9%)	2 (9.83%)						
Melaleuca	2 (9.7%)	2 (9.2%)	3 (7.6%)	3 (6%)	7 (4.3%)	Pro-Partner	200	43,300	30	288.7	
Herbalife	3 (6.7%)	5 (5.9%)	6 (5.1%)	4 (5.7%)	6 (5.1%)	Herbalife	66	69,486	91	50.5	
Nu Skin	5 (6.1%)	3 (8.3%)	4 (6.1%)	5 (5.6%)	3 (5.5%)						
Market	7 (4%)	6 (4.6%)	5 (5.4%)	6 (5.3%)	5 (5.2%)	Nu Skin	120	40,000	219	21.9	
America						Melaleuca	180	21,111	502	7.6	
Total Swiss	9 (0.8%)	8 (1.6%)	7 (4.2%)	7 (5.3%)	4 (5.2%)						
Jeunesse	10 (0.7%)	9 (1.2%)	10 (1.8%)	8 (3.3%)	8 (4.0%)	Amway	350	33,857	289	41.0	
E.EXCEL	8 (2.7%)	7 (3.1%)	9 (2.9%)	9 (2.9%)	10 (2.6%)	Jeunesse	180	19,444	23	152.2	
Avon	6 (4.6%)	6 (4.6%)	8 (4%)	10 (2.6%)	>10 (N.A.)		100	13,444	25	152.2	

Source: Company data, FTC, Taiwan Association of Direct Selling

Source: Taiwan Association of Direct Selling



### China Health Food Industry

- China's health food industry delivered a 30% CAGR between 2009-2016, mainly driven by economic growth, disposable income, and rising health awareness.
- Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 30% in 2016, according to Euromonitor.
- Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.





# 葡萄王生技

#### Our Goals and Strategies

confidential

### "Our Group Goals

#### Long-term Goals

- Transform Grape King into a group enterprise.
- Continue to explore partnership or new business opportunities and take the Group to international level.
- Grape King own brand, Pro-Partner, and Grape King Shanghai each to contribute 1/3 of consolidated revenue.

#### **Mid-term Goals**


- Continue overseas expansion.
- Establish retail channels in China for the 5 Blue Hat products.
- China business to continue delivering double digit growth.

#### **Near-term Goals**

- Continue to improve brand equity.
- Continue to invest in food safety measures and protection.
- Smooth ramp-up for our capacity expansion.
- Consolidated revenue to resume to double-digit growth.



# Integrated Marketing Strategy



#### Creative Brand Building & Product Campaigns

顧客

健康是 陪伴

Grape King Antrodia King (liver protection) Anger causes high blood pressure but also harms liver. Grape King Ginseng Vitamin B Complex Plus Flight attendant no longer needs to roll her eyes for unreasonable requests

Grape King's micro film commercial series Who do you want to deliver health to? Health is mom's handmade rice dumpling (Health is Accompanying) Grape King's micro film commercial series E R R B B B R E 目 任 Who do you want to deliver health to? Health is a 3 bedroom house (Health is Responsibility)



葡萄萄酸核合軟骨素、 膠原蛋白、碳酸钙、繊生素D等多種成分

11名目在享受生了



潘蒼鈞 33歲

### **Wew Products Pipeline**



#### **Ongoing Research for Future Products**



- Hericium Erinaceus (Lion's Mane mushroom) -Alleviate cognitive impairment (Chung Shan Medical University Hospital) - first phase unblind
- Hericium Erinaceus (Lion's Mane mushroom) Alleviate diplacusis (Dalin Tzu Chi Hospital)
- Hericium Erinaceus (Lion's Mane mushroom) Alleviate Parkinson's disease (Chung Shan Medical University Hospital)
- Lactobacillus Reduce body fat formation (China Medical University Hospital



#### Fungal-based – Animal Trials



- Research on Hericium Erinaceus (Lion's Mane mushroom) mycelia related to depression and sleep disorder (National Taiwan University)
- iPSC testing of Hericium Erinaceus mycelia on Alzheimer's disease patients; potential for treating dementia (National Yang-Ming University)
- Using big data to find and develop health foods
   Antrodia Camphorate substances (National Yang-Ming University)
- Protective uses of Hericium Erinaceus substances on ischemic brain injury (National Yang-Ming University)





- Super 13 Pro & Prebiotics Desensitizes and improves intestinal flora (China Medical University)
- Selective trials of Lactobacilli lowering blood sugar (OGTT) (Food Industry Research and Development Institute)
- Selective trials of Lactobacilli preventing depression (Hungkuang University)
- Trials for prevention of cisplatin (chemotherapy medication)- induced autoimmune kidney disorder (China Medical University)



- 995 alleviation of sarcopenia (Fu Jen Catholic University)
- Analysis of the prevention of spermatozoa damage and the promotion of spermatozoa quality using Morchella vulgaris
- Cicada active substance selected using mode for lowering intraocular pressure (ITRI)

### **<sup>66</sup> 2019 Production Line Expansion Plans**

			Manufa	acturing capacity				
Region	Factory	Production Line	2018 Monthly Capacity	2019 Monthly Capacity Added	2019 Monthly	Capacity	Increase Rate	Completion
	Grape King	Capsules	8 million capsules	5 million capsules	13 million c	apsules	60%	Q4
	Headquarter	Fine Granule	15 million pack	-	15 million	pack	-	-
	Pingzhen	Powder	1.8 million packs	-	1.8 million	packs	-	-
		Capsules	7 million capsules	-	7 million ca	psules	-	-
Taoyuan	aoyuan Grape King	Fine Granule	2 million pack	-	2 million	pack	-	-
	Specialist	Liquids-Big CC	4.2 million bottles	-	4.2 million	bottles	-	-
	Fermentation	Liquids-Small CC	1 million bottles	-	1 million b	ottles	-	-
	Zhongli	PKL	1.4 million bottles	-	1.4 million	bottles	-	-
		PIC/S	0.8 million packs	-	0.8 million	packs	-	-
	Grape King	Liquids(Glass)	15 million bottles	3 million bottles	18 million	bottles	20%	Q4
	Shanghai	Liquids(Retort Pouch)	-	3 million packs	3 million packs		New	Q3
Shanghai	Headquarter	Powder	8.2 million pack	6.8 million pack	15 million pack		83%	Q3
	Shanghai Capsules		-	7 million capsules	7 million ca	apsules	New	Q3
	Shanghai	Troches	23 million capsules	40 million capsules	63 million c	apsules	174%	Q3
			Ferme	ntation capacity				
Region	Factory	Production Line	2018 Fermentation Capacity	2019 Fermentation Capacity Added	2019 Fermentation Capacity	Fermenter	Increase Rate	Completion
	Grape King Bio-	Lactobacilli	-	30 tons	30 tons	15 tons*2	New	Q3
	Tech Research Institute Longtan	Mushroom	-	60 tons	60 tons	20 tons 40 tons	New	Q3
		Lactobacilli	25 tons	-	25 tons	5 tons*3 10 tons	-	-
	Grape King Specialist Fermentation Zhongli*	Mushroom	161.5 tons	-	161.5 tons	1 tons*6 2.5 tons 3 tons 20 tons 40 tons*2 50 tons	-	-
		PKL Liquids	80 tons	-	80 tons	20 tons*2 40 tons	-	-

#### 葡萄王生技

\* : The total volume of fermenter below 1 ton is about 18.5 tons.

### **Gur CSR Commitments**






### 葡萄王生技

#### **Financial Performance**


confidential

# **Financial Highlights**



Notes: Only 2017-2018 revenues were adjusted to IFRS 15


Historical EPS vs. ROCE



EPS (NT\$) LHS ROCE



Note: Only 2017-2018 were adjusted to IFRS 15. The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.



Cash dividend per share (NT\$) LHS **Dividend** payout





### **Five-Year Income Statement**

NT\$m	2012	2014	2015	2010	2017	2010			YoY (	%)		
N I ŞI II	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
Revenue	5,639	6,283	7,248	9,185	8,546	9,183	22.3	11.4	15.4	26.7	2.2	7.5
Gross Profit	4,983	5,561	6,385	7,919	7,023	7,329	23.7	11.6	14.8	24.0	(0.7)	4.4
Operating Expenses	(3,653)	(3,961)	(4,573)	(5,685)	(4,768)	(4,979)	19.4	8.4	15.4	24.3	(1.3)	4.4
Operating Profit	1,330	1,600	1,812	2,234	2,254	2,350	37.3	20.3	13.3	23.3	0.9	4.2
Non Operating Income/(Loss)	97	89	70	78	151	77	106.7	(8.1)	(21.5)	11.8	92.6	(49.2)
Pretax Income	1,427	1,689	1,883	2,312	2,405	2,427	40.5	18.4	11.4	22.8	4.0	0.9
Tax Expenses	(246)	(303)	(336)	(426)	(471)	(537)	36.8	23.1	10.9	26.8	10.6	14.0
Minority interest	(346)	(444)	(495)	(590)	(583)	(595)	52.0	28.4	11.5	19.2	(1.3)	2.1
Net Income to Parent	836	942	1,052	1,297	1,352	1,295	37.4	12.8	11.6	23.3	4.3	(4.2)
Basic EPS (NT\$)	6.42	7.24	8.07	9.82	10.03	9.57	37.5	12.8	11.5	21.7	2.1	(4.6)
Key Financial Ratios (%)												
Gross Margin	88.4	88.5	88.1	86.2	82.2	79.8						
Operating Expense Ratio	64.8	63.1	63.1	61.9	55.8	54.2						
Operating Margin	23.6	25.5	25.0	24.3	26.4	25.6						
Effect Tax Rate	17.2	17.9	17.8	18.4	19.6	22.1						
Net Margin	14.8	15.0	14.5	14.1	15.8	14.1						

Notes: Only 2017-2018 numbers were adjusted to IFRS 15



### **Five-Year Balance Sheet**

NITÉ	2012	2014	2015	2016	2017	2010	YoY (%)					
NT\$m	2013	2014	2015	2016	2017	2018	2013	2014	2015	2016	2017	2018
Total Assets	4,629	5,369	8,612	9,550	9,892	10,648	19.4	16.0	60.4	10.9	3.6	7.6
Cash	1,069	1,374	1,433	1,899	1,920	2,050	(1.5)	28.6	4.3	32.6	1.1	6.8
AR & NR	86	98	97	204	160	171	(38.1)	14.0	(1.9)	111.6	(21.5)	6.8
Inventories	235	268	359	435	492	563	11.3	14.1	34.0	21.0	13.1	14.4
Fixed Assets	1,820	2,068	5,597	6,084	6,355	5,927	15.5	13.6	170.6	8.7	4.5	(6.7)
Total Liabilities	1,408	1,652	4,393	3,767	3,564	3,715	21.9	17.3	165.9	(14.3)	(5.4)	4.2
AP & NP	88	128	153	198	323	262	(0.4)	45.9	19.2	29.6	63.2	(18.9)
Total Borrowing	32	0	2,439	1,206	1,022	1,119	4.1	-	- 1	(50.6)	(15.2)	9.5
Total Equity	3,221	3,717	4,220	5,783	6,328	6,933	18.4	15.4	13.5	37.1	9.4	9.6
Key Financial Ratios (%)												
A/R Turnover Days	7.2	5.3	4.8	5.9	7.0	6.5						
Inventory Turnover Days	122.4	125.6	131.0	113.0	109.5	102.4						
A/P Turnover Days	48.3	53.9	58.6	49.9	61.6	56.8						
Cash Conversion Days	81.3	77.0	77.2	69.0	54.9	52.1						
ROE (%)	32.2	32.3	32.1	31.3	27.0	23.7						
ROA (%)	19.7	18.9	15.0	14.3	13.9	12.6						
Net debt (cash)/Equity %	(32.2)	(37.0)	23.9	(12.0)	(14.2)	(13.4)						



# Dividend Payout and Capex

(NT\$m)	2012	2013	2014	2015	2016	2017	2018
Net profit	619	836	942	1,052	1,297	1,352	1,295
Cash dividend	482	651	690	730	862	903	883
DPS (NT\$)	3.7	5.0	5.3	5.59	6.4	6.68	6.5
Payout ratio	77.9%	77.9%	73.2%	69.4%	66.5%	66.8%	67.9%
Cash yield	3.1%	3.4%	2.4%	2.6%	3.2%	2.9%	3.2%
Сарех	159	355	187	2,635	736	772	1,116

#### Notes:

- 1. Cash yield is calculated based on Grape King's closing share price before the ex-dividend day of the following year, except for 2018, which is based on closing price on March 18, 2019.
- The big spike in capex in 2015-2018 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.



# **2019** Priorities

#### Taiwan Domestic Market

- Continue to work on our Brand, Products, and Business refresh through realignment of our organization structure and distribution channels
- Solidify our leadership position in Taiwan health food market
- Continue to identify and innovate quality products that meet consumers' needs
- Finding new channels (e.g. Restaurants, new distributors, Grape King visitors center)

#### **Overseas Market**

- Continue to maximize or wallet share in our existing clients in China and explore new OEM/ODM opportunities in Asia
- Looking for Global partners and OEM/ODM clients
- Complete product certifications in major Southeast Asian countries
- Establish retail channels for our own brand products in China

#### **Financial Performance**

- Positive revenue growth in 2019 with stable net profit margin
- Sustainable ROE of over 20%
- Maintain cash dividend payout of over 60%





# 葡萄王生技

#### **Thank You**

For more information, please visit our company website at www.grapeking.com.tw

confidential